What's New? Forum Discussions
  Events and What's Happening
Join GRACE in person or via live webcast for Not Your Father's Squamous Lung Cancer - for patients & caregivers living with squamous lung cancer, on Friday, November 4th, 2016 from 2-4:30pm ET in North Carolina.  This forum is presented in collaboration with the University of North Carolina Lineberger Comprehensive Cancer Center and the Lung Cancer Initiative of North Carolina, and made possible by support from Bristol Meyers Squibb, Celgene, and Genentech.
Please see the agenda for complete details!
Recent GRACE News and Posts
On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung Cancer Patient Forum in Aurora Colorado. We are happy to continue to share more videos from this live and webcast forum.
The afternoon sessions consisted of breakout survivorship sessions, each dealing with important issues that patients and caregivers deal with in everyday lives.  The latest video available is the ninth video from the webcast series, Bankruptcy and Workplace Discrimination with Patricia McMahon and Carlos Colon, AFC.
In the eighth video now available from the Targeted Therapies in Lung Cancer Patient Forum webcast series, GRACE presents the lunchtime keynote discussion: The Evolving Landscape of Molecular Testing in Lung Cancer: Who, How and When? featuring Dr. Dara Eisner.
We were pleased to be joined at our Targeted Therapies in Lung Cancer Patient Forum by lung cancer advocate and distinguished guest, Chris Draft.  In our seventh video,  GRACE founder Dr. Jack West presents the Lung Cancer Champion Award during the lunch time sessions.
Our sixth video is the final video from the morning breakouts.  This forum breakout session for EGFR patients and caregivers, featured co-chairs Dr. Greg Riely and Dr. Jack West, and patient moderator Bob Fuerst.
Amidst all of the glowing reports about immunotherapy for lung and many other cancers, it would be understandable for patients and physicians to be tempted to rush toward prioritizing immunotherapy as the first treatment strategy to pursue. In fact, a highly publicized trial called KEYNOTE-024 was just presented at the ESMO meeting in Copenhagen and demonstrated a significant improvement in progression-free and overall survival over standard chemotherapy doublet treatment as the first line approach for patients with high level expression of the PD-L1 protein on their tumor (about 30% of patients).  But there is also converging evidence...